Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

• Main Authors: Xuemin Jiang (Author), Russ Wada (Author), Bill Poland (Author), Huub Jan Kleijn (Author), Bin Fan (Author), Guowen Liu (Author), Hua Liu (Author), Stephanie Kapsalis (Author), Hua Yang (Author), Kha Le (Author)
• Format: Book
• Published: Wiley, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Ivosidenib is a once daily (q.d.), orally available, potent mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor approved for treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and intensive chemotherapy ineligible AML with a susceptible IDH1 mutation. Popul...